CCN3: a novel antifibrotic treatment?

点击翻译按钮获取中文摘要

Fibrotic diseases such as scleroderma have no therapy. These diseases are characterized by extensive scar tissuedeposition. The cells (fibroblasts) within the scar are subject to enhanced tension due to the surrounding scar tissue. Theyalso themselves are abnormal in that they exert excessive tension on the scar tissue. It is believed that this excessivetension is responsible for the maintenance of the scar. A protein called CCN2 is expressed specifically in scar tissue andpromotes this tension. A related protein CCN3 is not found in scar tissue, but normally acts to inhibit CCN2. We want to testwhether CCN3 (and peptides derived from CCN3) can block scleroderma fibrosis. Moreover, we want to test if monitoringthe CCN2:CCN3 ratio in patients can be used to monitor disease progression At the end of the funding period, we will designandinitiate clinical trials with our peptides to see if we can block fibrosis clinically.